Decreased Skeletal Muscle Mitochondrial DNA in Patients Treated with High-Dose Simvastatin
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Statins are generally well tolerated, but can cause myopathy1 and have been associated with mitochondrial abnormalities.2,3,4,5,6 The aim of this study was to determine whether muscle mitochondrial DNA (mtDNA) levels are altered during statin therapy. We retrospectively quantified mtDNA in 86 skeletal muscle biopsy specimens collected as part of a previously published7 clinical trial of high-dose simvastatin or atorvastatin versus placebo. Clinical Pharmacology & Therapeutics (2007) 81, 650–653. doi:10.1038/sj.clpt.6100124; published online 28 February 2007
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There was a positive overall correlation between changes in muscle ubiquinone and the change in mtDNA/nuclear DNA ratios (R = 0.63, P < 0.01), which was strongest in the simvastatin group (R = 0.76, P < 0.002).”
In the citing paper
“Decreased mitochondrial DNA (mtDNA): reduced levels were found in skeletal muscle biopsies taken from patients treated with simvastatin 80 mg/day for 8 weeks but not in those treated with atorvastatin 40 mg/day.83”
In the citing paper
“In hypercholesterolemic patients treated with simvastatin, the content of Q 10 in skeletal muscle was reduced, and this was paralleled by a reduction in mitochondrial content (estimated by citrate synthase [CS] activity and mitochondrial DNA content), but only when a lipophilic statin was used (simvastatin) (12,13).”
From Simvastatin Effects on Skeletal Muscle (2013) · cites this paper as [13]
In the citing paper
“Other studies with high simvastatin doses (80 mg/day) have reported decreased Q 10 protein content in muscle from simvastatin-treated patients (12,13), whereas studies using lower (20 mg/day) doses have been unable to demonstrate decreased muscle Q 10 protein content (14,15)”
From Simvastatin Effects on Skeletal Muscle (2013) · cites this paper as [13]
Citations
Cites
Thomas, A. C., & Campbell, J. H. (2000) · Cited by 2,800
Bruckert, E., Hayem, G., Dejager, S., Yau, C., & Bégaud, B. (2005) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-005-5686-z · Cited by 1,226 · cited 1×
“11 However, in a recent large French observational study (PRIMO)”
BackgroundJones, P., Kafonek, S., Laurora, I., & Hunninghake, D. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00965-x · Cited by 1,067
Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway
Brinkman, K., ter Hofstede, H. J. M., Burger, D. M., Smeitink, J. A. M., & Koopmans, P. P. (1998) · AIDS · doi:10.1097/00002030-199814000-00004 · Cited by 847
Mitochondrial Myopathy Caused by Long-Term Zidovudine Therapy
Dalakas, M. C., Illa, I., Pezeshkpour, G. H., Laukaitis, J. P., Cohen, B., & Griffin, J. L. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004193221602 · Cited by 844 · cited 1×
“Clinical symptoms and mitochondrial alterations in these patients are very similar to those observed in SIM”
ResultChanges in Mitochondrial DNA as a Marker of Nucleoside Toxicity in HIV-Infected Patients
Côté, H. C. F., Brumme, Z. L., Craib, K. J. P., Alexander, C. S., Wynhoven, B., Ting, L., Wong, H., Harris, M., Harrigan, P. R., O'Shaughnessy, M. V., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012035 · Cited by 573 · cited 1×
“Drug-related mitochondrial toxicity in the setting of HIV antiretroviral therapy has been associated with changes in mtDNA level”
BackgroundSelf-citationStatin-associated myopathy with normal creatine kinase levels
Phillips, P. S., Haas, R. H., Bannykh, S., Hathaway, S., Gray, N. L., Kimura, B. J., Vladutiu, G. D., England, J. D. F., & and the Scripps Mercy Clinical Research Center* (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-7-200210010-00009 · Cited by 565
High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial
PAIVA, H., THELEN, K., COSTER, R., SMET, J., PAEPE, B., MATTILA, K., LAAKSO, J., LEHTIMAKI, T., VONBERGMANN, K., & LUTJOHANN, D. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.03.006 · Cited by 308
Self-citationStatin-related adverse events: A meta-analysis
Silva, M. A., Swanson, A. C., Gandhi, P. J., & Tataronis, G. R. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.01.005 · Cited by 278 · cited 1×
“A recent meta-analysis of 18 randomized controlled trials at regular statin dose ( n e71,108) reported a higher rate of CK elevations, but a lower rate of myalgia in simvastatin than atorvastatin”
BackgroundAn Assessment of Statin Safety by Muscle Experts
Thompson, P. D., Clarkson, P. M., & Rosenson, R. S. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.013 · Cited by 259
Research works printed but not linked: 1
- Schalke B.B., 1992, N. Engl. J. Med, 327, 649
Cited by
Stroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv043 · Cited by 1,443
Statin Adverse Effects: A Review of the Literature and Evidence for a Mitochondrial Mechanism
Golomb, B. A., & Evans, M. A. (2008) · American Journal of Cardiovascular Drugs · doi:10.2165/0129784-200808060-00004 · Cited by 677
An assessment by the statin muscle safety task force: 2014 update
Rosenson, R. S., Baker, S. K., Jacobson, T. A., Kopecky, S. L., & Parker, B. A. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.03.004 · Cited by 485
Effects of statins on mitochondrial pathways
Mollazadeh, H., Tavana, E., Fanni, G., Bo, S., Banach, M., Pirro, M., von Haehling, S., Jamialahmadi, T., & Sahebkar, A. (2021) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12654 · Cited by 249
Simvastatin Impairs Exercise Training Adaptations
Mikus, C. R., Boyle, L. J., Borengasser, S. J., Oberlin, D. J., Naples, S. P., Fletcher, J., Meers, G. M., Ruebel, M., Laughlin, M. H., Dellsperger, K. C., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.074 · Cited by 243
“effects on skeletal muscle mitochondrial function ((13-18,27-30,32).”
ResultIntolerance to Statins: Mechanisms and Management
Bitzur, R., Cohen, H., Kamari, Y., & Harats, D. (2013) · Diabetes Care · doi:10.2337/dcs13-2038 · Cited by 179
Simvastatin Effects on Skeletal Muscle
Larsen, S., Stride, N., Hey-Mogensen, M., Hansen, C. N., Bang, L. E., Bundgaard, H., Nielsen, L. B., Helge, J. W., & Dela, F. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.036 · Cited by 165
Myotoxicity of statins: Mechanism of action
du Souich, P., Roederer, G., & Dufour, R. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.029 · Cited by 161
Mechanisms of statin-associated skeletal muscle-associated symptoms
Bouitbir, J., Sanvee, G. M., Panajatovic, M. V., Singh, F., & Krähenbühl, S. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.010 · Cited by 136
The role of mitochondria in statin‐induced myopathy
Apostolopoulou, M., Corsini, A., & Roden, M. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12461 · Cited by 140
Therapeutic use of coenzyme Q10and coenzyme Q10-related compounds and formulations
Villalba, J. M., Parrado, C., Santos-Gonzalez, M., & Alcain, F. J. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543781003727495 · Cited by 135
Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms
Okuyama, H., Langsjoen, P. H., Hamazaki, T., Ogushi, Y., Hama, R., Kobayashi, T., & Uchino, H. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1011125 · Cited by 122
The genetics of statin-induced myopathy
Ghatak, A., Faheem, O., & Thompson, P. D. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.11.033 · Cited by 126
Differential effects of statins on endogenous H2S formation in perivascular adipose tissue
Wójcicka, G., Jamróz-Wiśniewska, A., Atanassova, P. K., Chaldakov, G. N., Chylińska-Kula, B., & Bełtowski, J. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.10.011 · Cited by 98
Statins, Muscle Disease and Mitochondria
Ramachandran, R., & Wierzbicki, A. S. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6080075 · Cited by 96
Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins
Sirvent, P., Fabre, O., Bordenave, S., Hillaire-Buys, D., Raynaud De Mauverger, E., Lacampagne, A., & Mercier, J. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2012.01.008 · Cited by 90
“These results contrast with those from a randomized controlled trial showing a reduced activity of complexes 2, 3 and 4 of the respiratory chain due to a decrease in mitochondrial volume following treatment with high doses of simvastatin (Paiva et al., 2005; Schick et al., 2007).”
ResultNLA Task Force on Statin Safety - 2014 update
Jacobson, T. A. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.03.003 · Cited by 97
Decreased skeletal muscle mitochondrial DNA in patients with statin-induced myopathy
Stringer, H. A. J., Sohi, G. K., Maguire, J. A., & Côté, H. C. F. (2013) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.12.023 · Cited by 79
Self-citationEdwards, I. R., Star, K., & Kiuru, A. (2007) · Drug Safety · doi:10.2165/00002018-200730060-00005 · Cited by 88
Molecular mechanisms of statin intolerance
Gluba-Brzózka, A., Franczyk, B., Toth, P. P., Rysz, J., & Banach, M. (2016) · Archives of Medical Science · doi:10.5114/aoms.2016.59938 · Cited by 81
Curcumin: an effective adjunct in patients with statin-associated muscle symptoms?
Sahebkar, A., Saboni, N., Pirro, M., & Banach, M. (2017) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12140 · Cited by 72
Solomon, T. P. J. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00896 · Cited by 70
Özek, N. Ş., Bal, I. B., Sara, Y., Onur, R., & Severcan, F. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.09.010 · Cited by 78
Muscle Toxicity of Drugs: When Drugs Turn Physiology into Pathophysiology
Janssen, L., Allard, N. A. E., Saris, C. G. J., Keijer, J., Hopman, M. T. E., & Timmers, S. (2019) · Physiological Reviews · doi:10.1152/physrev.00002.2019 · Cited by 78
Wu, J. S., Buettner, C., Smithline, H., Ngo, L. H., & Greenman, R. L. (2011) · Muscle & Nerve · doi:10.1002/mus.21847 · Cited by 61
Bonifacio, A., Mullen, P. J., Mityko, I. S., Navegantes, L. C. C., Bouitbir, J., & Krähenbühl, S. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1378-4 · Cited by 64
Statins Affect Skeletal Muscle Performance: Evidence for Disturbances in Energy Metabolism
Allard, N. A. E., Schirris, T. J. J., Verheggen, R. J. H. M., Rüssel, F. G. M., Rodenburg, R. J., Smeitink, J. A. M., Thompson, P. D., Hopman, M. T. E., & Timmers, S. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01561 · Cited by 66
Statin myopathy as a metabolic muscle disease
Phillips, P. S., & Haas, R. H. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.7.971 · Cited by 56
Wong, J., McLennan, S. V., Molyneaux, L. M., Min, D., Twigg, S. M., & Yue, D. K. (2009) · Diabetologia · doi:10.1007/s00125-009-1424-6 · Cited by 58
“Another factor that may have impacted on the age of onset:mtDNA relationship in the complications group is the use of medications such as TZDs and statins [ 42 ,43].”
BackgroundTrogden, K. P., Battaglia, R. A., Kabiraj, P., Madden, V. J., Herrmann, H. O., & Snider, N. T. (2018) · The FASEB Journal · doi:10.1096/fj.201700663r · Cited by 59
“Themolecular mechanisms of statin intolerance are poorly understood, and cytoskeletal and other structural or scaffolding proteins have not been implicated thus far (42); however, a previous study found a significant decrease in skeletal muscle mitochondrial DNA in patients who received simvastatin therapy (43).”
BackgroundHigh-dose statin use does not impair aerobic capacity or skeletal muscle function in older adults
Traustadóttir, T., Stock, A. A., & Harman, S. M. (2008) · AGE · doi:10.1007/s11357-008-9070-3 · Cited by 53
Golomb, B. A., Kwon, E. K., Koperski, S., & Evans, M. A. (2009) · Drug Safety · doi:10.2165/00002018-200932080-00004 · Cited by 53
Coenzyme Q10 and Statin Myalgia: What is the Evidence?
Mas, E., & Mori, T. A. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0134-3 · Cited by 51
“In this regard, Schick et al. [ 38 ] have shown decreased mtDNA with simvastatin with normal CK levels and no muscle complaints, consistent with decreased mitochondrial mass.”
BackgroundThe effects of statins on exercise and physical activity
Noyes, A. M., & Thompson, P. D. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.07.003 · Cited by 47
Sailler, L., Pereira, C., Bagheri, A., Lapeyre‐Mestre, M., Montastruc, J., Arlet, P., Arlet‐Suau, E., Uro‐Coste, E., Roussel, H. M., Adoué, D., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.075523 · Cited by 42
Özek, N. Ş., Sara, Y., Onur, R., & Severcan, F. (2009) · Bioscience Reports · doi:10.1042/bsr20080150 · Cited by 49
Duncan, A. J., Hargreaves, I. P., Damian, M. S., Land, J. M., & Heales, S. (2008) · Toxicology Mechanisms and Methods · doi:10.1080/15376510802305047 · Cited by 42
Southern, W. M., Nichenko, A. S., Shill, D. D., Spencer, C. C., Jenkins, N. T., McCully, K. K., & Call, J. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172551 · Cited by 41
Goodman, C. A., Derk, P., Zacharewicz, E., Lee, R. S., Snow, R. J., Russell, A. P., & McConell, G. K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128398 · Cited by 37
Mitochondrial disorders and drugs: what every physician should know
Orsucci, D., Ienco, E. C., Siciliano, G., & Mancuso, M. (2019) · Drugs in Context · doi:10.7573/dic.212588 · Cited by 37
Panayiotou, G., Paschalis, V., Nikolaidis, M. G., Theodorou, A. A., Deli, C. K., Fotopoulou, N., Fatouros, I. G., Koutedakis, Y., Sampanis, M., & Jamurtas, A. Z. (2012) · Scandinavian Journal of Medicine and Science in Sports · doi:10.1111/j.1600-0838.2011.01437.x · Cited by 38
Statins: Neurobiological underpinnings and mechanisms in mood disorders
Walker, A. J., Kim, Y., Borissiouk, I., Rehder, R., Dodd, S., Morris, G., Nierenberg, A. A., Maes, M., Fernandes, B. S., Dean, O. M., et al. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.07.012 · Cited by 33
The Effects of Statin Medications on Aerobic Exercise Capacity and Training Adaptations
Murlasits, Z., & Radak, Z. O. (2014) · Sports Medicine · doi:10.1007/s40279-014-0224-4 · Cited by 34
“only 8 weeks of simvastatin treatment [93].”
Drugs and mitochondrial diseases: 40 queries and answers
Mancuso, M., Orsucci, D., Filosto, M., Simoncini, C., & Siciliano, G. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.657177 · Cited by 36
Atorvastatin-induced cell toxicity in yeast is linked to disruption of protein isoprenylation
Callegari, S., McKinnon, R. A., Andrews, S., & de Barros Lopes, M. A. (2010) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2009.00593.x · Cited by 28
Exercise-Pharmacology Interactions: Metformin, Statins, and Healthspan
Miller, B. F., & Thyfault, J. P. (2020) · Physiology · doi:10.1152/physiol.00013.2020 · Cited by 33
The interactions of some commonly consumed drugs with mitochondrial adaptations to exercise
Robinson, M. M., Hamilton, K. L., & Miller, B. F. (2009) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00343.2009 · Cited by 32
Meex, R. C. R., Phielix, E., Schrauwen‐Hinderling, V. B., Moonen‐Kornips, E., Schaart, G., Schrauwen, P., & Hesselink, M. K. C. (2010) · Clinical Science · doi:10.1042/cs20100153 · Cited by 33
Modulation of H 2 S Metabolism by Statins: A New Aspect of Cardiovascular Pharmacology
Bełtowski, J., & Jamróz-Wiśniewska, A. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2011.4358 · Cited by 27
Abbas, A., Milles, J. J., & Ramachandran, S. (2012) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.4137/cmed.s7591 · Cited by 34
RYAN, T. E., Torres, M. J., Lin, C., Clark, A. H., Brophy, P. M., Smith, C. A., Smith, C. D., Morris, E. M., Thyfault, J. P., & Neufer, P. D. (2024) · JCI Insight · doi:10.1172/jci.insight.174125 · Cited by 28
“…function are thought to contribute to the development of statin-induced myopathy, including altered calcium homeostasis (32, 82), decreased ubiquinone content (Coenzyme Q10) (83) and respiratory function (29–31, 34, 82), reduced mitochondrial DNA content (84), and induced muscle atrophy (85).”
BackgroundWilliams, P. T., & Thompson, P. D. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.06.019 · Cited by 27
Ren, L., Xuan, L., Han, F., Zhang, J., Gong, L., Lv, Y., Zhang, W., Yang, S. T., Xu, B., Yan, Y., et al. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115076 · Cited by 29
Corsetti, G., D’Antona, G., Ruocco, C., Stacchiotti, A., Romano, C., Tedesco, L., Dioguardi, F. S., Rezzani, R., & Nisoli, E. (2014) · Amino Acids · doi:10.1007/s00726-014-1772-5 · Cited by 24
Statin associated muscle symptoms (SAMS): strategies for prevention, assessment and management
Iatan, I., Mancini, G. B. J., Yeoh, E., & Hegele, R. A. (2023) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2215982 · Cited by 29
Hsieh, A. Y. Y., Budd, M. A., Deng, D., Gadawska, I., & Côté, H. C. F. (2018) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2018.05.001 · Cited by 23
Self-citationPGC-1β modulates statin-associated myotoxicity in mice
Singh, F., Zoll, J., Duthaler, U., Charles, A., Panajatovic, M. V., LAVERNY, G., McWilliams, T. G., METZGER, D., Gény, B., Krähenbühl, S., et al. (2018) · Archives of Toxicology · doi:10.1007/s00204-018-2369-7 · Cited by 26
“Inhibition of mitochondrial biogenesis by statins has been demonstrated, since skeletal muscle mitochondrial DNA is decreased in patients with statin-induced myopathy (Schick et al. 2007; Stringer et al. 2013).”
BackgroundShah, M., Shrestha, K., Tseng, C., Goyal, A., Liewluck, T., & Gupta, L. (2024) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.15337 · Cited by 30
Windt, A. D., Rai, M., Kytömäki, L., Thelen, K., Lütjohann, D., Bernier, L., Davignon, J., Soini, J. T., Pandolfo, M., & Laaksonen, R. (2007) · DNA and Cell Biology · doi:10.1089/dna.2006.0570 · Cited by 20
“…observed that high-dose cholesterol lowering with HMG-CoA (3-hydroxy-3-Table methylglutaryl coenzyme A) reductase inhibitors (statins) in patients results in mtDNA depletion and induction of proapoptotic and proinflammatory pathways in skeletal muscle (Laaksonen et al ., 2006; Schick et al ., 2007).”
Self-citationPhysical activity in statin-treated patients
Mascitelli, L., & Pezzetta, F. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2007.12.048 · Cited by 19
Golightly, L. K., Barber, G. R., Barron, M. A., & Page, R. L., II (2013) · Drug metabolism and drug interactions · doi:10.1515/dmdi-2012-0033 · Cited by 19
Statin-Associated Cardiomyopathy Responds to Statin Withdrawal and Administration of Coenzyme Q 10
Langsjoen, P. H., Langsjoen, J., Langsjoen, A. M., & Rosenfeldt, F. (2019) · The Permanente Journal · doi:10.7812/tpp/18.257 · Cited by 22
Statins interfere with the attachment of S. cerevisiae mtDNA to the inner mitochondrial membrane
Cirigliano, A., Amelina, A., Biferali, B., Macone, A., Mozzetta, C., Bianchi, M. M., Mori, M., Botta, B., Pick, E., Negri, R., et al. (2019) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2019.1687461 · Cited by 15
Singla, M., Rastogi, A., Aggarwal, A. N., Bhat, O. M., Badal, D., & Bhansali, A. K. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12541 · Cited by 17
Statin-induced Myopathy in Skeletal Muscle: the Role of Exercise
Kwak, H. (2014) · Journal of Lifestyle Medicine · doi:10.15280/jlm.2014.4.2.71 · Cited by 18
Hou, T., Li, Y., Chen, W., Heffner, R. R., & Vladutiu, G. D. (2017) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-160184 · Cited by 15
Christiansen, L. B., Dohlmann, T. L., Ludvigsen, T. P., Parfieniuk, E., Ciborowski, M., Szczerbiński, Ł., Kretowski, A. J., Desler, C., Tiano, L., Orlando, P., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-81846-9 · Cited by 13
Molecular mechanisms of toxicity of simvastatin, widely used cholesterol-lowering drug. A review
Kaminsky, Y. G., & Kosenko, E. A. (2010) · Open Medicine · doi:10.2478/s11536-009-0123-5 · Cited by 13
Lipid-lowering Therapies in Myositis
Mizus, M. C., & Tiniakou, E. (2020) · Current Rheumatology Reports · doi:10.1007/s11926-020-00942-3 · Cited by 11
Polypharmacy and sun exposure: Implications for mitochondrial DNA deletions in skin
Powers, J. M., MURPHY, G. M., Ralph, N., O’Gorman, S. M., & Murphy, J. E. (2017) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2017.06.020 · Cited by 11
Myopathy associated with chronic orlistat consumption: A case report
Ringman, J. M., & Mozaffar, T. (2008) · Neuromuscular Disorders · doi:10.1016/j.nmd.2008.03.005 · Cited by 10
“Induction of an autoimmune response against muscle [2,3], precipitation of mitochondrial dysfunction in susceptible individuals [4,5] and depletion of substrates for synthesis of coenzyme Q10 [6,7] or other important metabolic intermediaries have all been postulated.”
Drug-Induced Mitochondrial Toxicity
Massart, J., Borgne‐Sanchez, A., & Fromenty, B. (2018) · Springer eBooks · doi:10.1007/978-3-319-73344-9_13 · Cited by 12
Improvement in sleep apnoea associated with switch from simvastatin to pravastatin: Figure 1
Cham, S., Gill, K., Koperski, S., & Golomb, B. A. (2009) · BMJ Case Reports · doi:10.1136/bcr.05.2009.1875 · Cited by 7
Mécanismes d’action directs mis en jeu dans les myopathies toxiques
Khelfi, A., Azzouz, M., Abtroun, R., Reggabi, M., & Alamir, B. (2017) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2017.04.002 · Cited by 6
Callegari, S., Gregory, P. A., Sykes, M. J., Bellon, J., Andrews, S., McKinnon, R. A., & Lopes, M. D. B. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002755 · Cited by 8
“Although the various statins have been shown to differ in their cellular toxicity effects, all of them have been implicated with mitochondrial dysfunction [48,50,51,52,53].”
BackgroundSimvastatin monotherapy as a potential option for statin-associated muscle symptoms: a case report
Qu, H., Guo, M. H., Kou, N., Wu, H., Zhang, Y., Gao, Z., & Shi, D. (2016) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12419 · Cited by 3
Busanello, E. N. B., Marques, A. C. S., Lorza‐Gil, E., Oliveira, H. C. F., & Vercesi, A. E. (2018) · InTech eBooks · doi:10.5772/intechopen.71610 · Cited by 5
“Schick and colleagues also observed reduced mitochondrial DNA levels in patients treated with simvastatin [157].”
BackgroundPharmacogenomics of Cardiovascular Drugs
Baudhuin, L. M. (2012) · Wiley eBooks · doi:10.1002/9781119959601.ch7 · Cited by 4
Corsetti, G., & Pasini, E. (2026) · Nutrients · doi:10.3390/nu18050722 · Cited by 5
“Several mechanisms have been proposed, including mitochondrial dysfunction [48,49], disruption of intracellular signaling pathways [50], vitamin D deficiency [51], inhibition of the mevalonate pathway [52], genetic susceptibility [47], and underlying neuromuscular disorders [53].”
The Role of the Mitochondria in SAMS
Allard, N. A. E., & Timmers, S. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-33304-1_12 · Cited by 2
Blood cholesterol and mitochondrial toxicity of simvastatin
Kaminsky, Y. G., & Kosenko, E. A. (2011) · Biology Bulletin Reviews · doi:10.1134/s2079086411040013 · Cited by 2
Nonaka, K., Ozaki, Y., Ito, K., Sakita, M., Une, S., & Akiyama, J. (2018) · The Journal of Physiological Sciences · doi:10.1007/s12576-018-0649-x · Cited by 2
Pharmacogenetics of SLCO1B1 : Population genetics and effect on statins
Pasanen, M. K. (2008) · Helda - University of Helsinki Institutional Repository · Cited by 6
Bakar, N. S., & Salleh, N. N. H. N. (2025) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-025-00896-2 · Cited by 1
“Although not directly linked to MCT inhibition, simv-astatin’s impact on mitochondrial function has also been validated in a randomised controlled trial and prospective studies [74, 78], as well as in a series of case reports involving other statins [15, 73, 75, 77, 80].”
Sjúrðarson, T., Larsen, S., Jensen, S. B. K., Bejder, J., Rasmussen, J., Borg, S. Á., Kristiansen, J., Meinhardsson, J. M., Olsen, H. W., Ellingsgaard, H., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-101425 · Cited by 2
SIMVASTATIN INDUCES MITOCHONDRIAL LOSS AND PTEN-MEDIATED AUTOPHAGY
Lee, P. S. (2012) · California State University ScholarWorks (system-wide DSpace) · Cited by 2
Questioning the Safety of Life-long Statin Therapy in Patients With Peripheral Arterial Disease
Mascitelli, L., Pezzetta, F., Goldstein, M. R., & Samson, R. H. (2008) · Vascular and Endovascular Surgery · doi:10.1177/1538574408326184 · Cited by 1
Biosíntesis de coenzima Q: mantenimiento de la homeostasis redx y adaptación metabólica
Fernández, C. P. (2010) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Do statins interfere with physical activity in the treatment of metabolic syndrome?
Mascitelli, L., & Pezzetta, F. (2007) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2007.07.004
The Impact of Physical Activity on Statin-Associated Skeletal Muscle Myopathy
Chung, H. R., Wu, P.-T., Fitschen, P. J., Kistler, B. M., Park, H. W., Jeong, J. H., Wilund, K. R., Woods, J., & Boppart, M. D. (2015) · Medicine & Science in Sports & Exercise · doi:10.1249/01.mss.0000477291.98365.c0
Statins stimulate atherosclerosis and heart failure: pharmacological
Okuyama, H., Langsjoen, P. H., Hamazaki, T., Ogushi, Y., Hama, R., Kobayashi, T., & Uchino, H. (2015)
"ESTATINAS, MIOPATIA E EXERCÍCIO FÍSICO"
Blaj, R. N. (2014) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Statin-Induced Muscle Toxicity
Feng, Q., & Wilke, R. A. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-381510-1.00067-3
PGC-1β prevents statin-associated myotoxicity in oxidative skeletal musclePreprint
Singh, F., Zoll, J., Duthaler, U., Charles, A., LAVERNY, G., METZGER, D., Gény, B., Krähenbühl, S., & Bouitbir, J. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/218636
Skeletal Muscle Mitochondrial Toxicity
Herbert, E. K., Herbert, S., & Herbert, K. E. (2018) · Wiley eBooks · doi:10.1002/9781119329725.ch8 · Cited by 1
New therapeutics to modulate mitochondrial energy metabolism in neurodegenerative disorders
Orsucci, D., Ienco, E. C., Siciliano, G., & Mancuso, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819621-2.00023-1
(2008) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328317a234
Egan, B. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733721587.793550370
Selvasudha, N., Koumaravelou, K., & Sridurga Devi, N. (2017) · SM Analytical and Bioanalytical Techniques · doi:10.36876/smabt.1013s
Metadata
- Authors
- Schick, B. A., Laaksonen, R., Frohlich, J. J., Päivä, H., Lehtimäki, T., Humphries, K. H., & Côté, H. C. F.
- Affiliations
- University of British Columbia (CA)
- Tampere University Hospital (FI)
- Corresponding author
- Côté, H C F
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2007-02-28
- Volume
- 81
- Issue
- 5
- Pages
- 650-653
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2019193819
- Cited by
- 103
- References
- 21
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2023: 2 · 2021: 3 · 2020: 5 · 2019: 5 · 2018: 10 · 2017: 11 · 2016: 4 · 2015: 7 · 2014: 7 · 2013: 5 · 2012: 9
- FWCI
- 3.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Pharmacology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Michael Smith Health Research BC
- University of British Columbia
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
- Keywords
- simvastatin, statin-induced myopathy, skeletal muscle, mitochondrial DNA, high-intensity statin therapy, atorvastatin, mitochondrial abnormalities, statin adverse effects
- MeSH terms
- Atorvastatin, Adult, Aged, DNA, Mitochondrial, Double-Blind Method, Female, Heptanoic Acids, Humans, Hypercholesterolemia, Longitudinal Studies, Male, Middle Aged, Mitochondria, Muscle, Pyrroles, Retrospective Studies, Ubiquinone, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.